Lymphoma

Treatment tied to higher recovery odds and faster time to kidney recovery

FDA boxed warning led to multiple studies on the issue in 2024

News, features, and commentary about cancer-related issues

Studies show promising EFS, PFS, and OS at 3 to 8 years

Novel CD19xCD3 T-cell engager showed high response rate in phase I study

News, features, and commentary about cancer-related issues

Promising single-agent efficacy with manageable safety may reshape initial treatment

Experts talk about long-term data and the importance of infection prophylaxis

Alarming mental health challenges among young cancer survivors, especially males, demand action

Benefit seen in all prespecified subgroups, including high-risk patients

New standard of care for patients in first remission?

Two-thirds of phase II patients had a complete response at 12 weeks of treatment

Nearly half of women with unusual or nonreportable cfDNA-sequencing results had cancer

Benefit shown in trial of patients flagged for high risk of cardiotoxicity